Saturday 17 October 2026
Export DRIO’s income statement to Excel — free account
DarioHealth Corp.
DRIO Healthcare Health Information Services
DarioHealth Corp.’s revenue for fiscal 2025 (year ended December 2025) was $22.4 million, down 17.3% from fiscal 2024. In the quarter to June 2026, revenue fell 3.58%, EPS grew 76.4%, free cash flow was flat and total debt rose 1.85%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.95
0.18
−3.51%
Follow DRIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.20 | 2.03 | 2.49 | 2.94 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.41) | (7.70) | (8.76) | (10.14) | |
P/B ratio |
0.73 | 0.67 | 0.85 | 1.12 | |
Price to Tangible BV |
49.41 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.56 | 2.69 | 3.48 | 4.23 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.36) | (2.32) | (2.92) | (3.50) | |
EV/FCF |
(2.32) | (2.27) | (2.86) | (3.44) | |
Quick Ratio |
4.02 | 3.30 | 2.63 | 1.92 | |
Current Ratio |
4.55 | 3.76 | 3.07 | 2.31 | |
Net Debt/EBITDA |
0.18 | (0.54) | (1.57) | (2.82) | |
Debt/Assets |
26.01% | 27.93% | 29.95% | 32.16% | |
Debt/Equity |
0.41 | 0.45 | 0.50 | 0.56 | |
Asset Turnover |
0.22 | 0.20 | 0.19 | 0.21 | |
Operating CF/Net income |
0.39 | 0.57 | 0.73 | 0.77 | |
Capex/Depreciation |
(0.05) | (0.12) | (0.05) | (0.07) | |
Interest Coverage |
(9.66) | (2.16) | (6.36) | (5.77) | |
Research and Development Expense of Revenue |
66.47% | 50.35% | 42.71% | 40.56% | |
Selling, General and Administrative Expense of Revenue |
183.16% | 166.93% | 145.49% | 146.24% | |
Intangible Assets out of Total Assets |
0.63 | 0.67 | 0.71 | 0.75 | |
Share Based Compensation of Revenue |
58.92% | 38.96% | 25.81% | 12.21% | |
Graham Net Nets |
(0.01) | (0.16) | (0.23) | (0.31) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(64.32%) | (91.65%) | (110.72%) | (92.88%) | |
Free Cash Flow Yield |
(50.11%) | (58.34%) | (48.86%) | (41.89%) | |
Revenue per Share |
1.60 | 1.31 | 0.85 | 0.55 | |
Operating CF per Share |
(2.34) | (1.48) | (0.92) | (0.65) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.36) | (1.48) | (0.92) | (0.65) | |
Cash per Share |
10.24 | 6.59 | 3.08 | 1.53 | |
Shareholders Equity per Share |
23.88 | 17.05 | 9.48 | 5.90 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
23.88 | 17.05 | 9.48 | 5.90 | |
Free Cash Flow |
(7.39) | (5.91) | (6.05) | (6.12) | |
Working Capital |
32.91 | 25.74 | 19.38 | 12.55 | |
Capital Expenditures |
(0.04) | (0.03) | (0.03) | (0.04) | |
Net Current Asset Value |
(0.61) | (7.09) | (12.17) | (19.38) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.78 | 5.82 | 5.10 | 4.77 | |
Average Payables |
3.06 | 2.99 | 3.11 | 3.28 | |
Average Inventory |
4.81 | 4.53 | 4.40 | 4.16 | |
Average Assets |
113.84 | 114.48 | 109.44 | 102.46 | |
Average Common Equity |
66.72 | 69.97 | 68.04 | 59.54 |
Columns are period end dates